Public health: ‘Either we all live in a decent world, or nobody does’
HQ Team In our search for websites and organizations engaged in community health, public policy and similar endeavors, we came across âThe Third.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team In our search for websites and organizations engaged in community health, public policy and similar endeavors, we came across âThe Third.
The US regulator has extended a review of an application by Organon & Co.âs atopic dermatitis (eczema) drug by three months with a.
Malaria, HIV, and tuberculosis were among a list of 17 disease-causing pathogens where vaccines need to be developed as a priority to reduce.
The UK, along with a clutch of government and private entities, has set afoot plans to create the worldâs first real-time surveillance system.
Britain has detected two cases of Clade Ib mpox, a variant, in household contacts of the first case, taking the total to three.
HQ Team November 3, 2024: The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability.
Malaria killed 1,157 people in Ethiopia during the first ten months of this year, and 7.3 million cases were reported in the landlocked.
The EU faces a new set of healthcare challenges potentially more potent than the Covid-19 pandemic, and some states are âmiles awayâ from.
Danish multinational pharmaceutical company Novo Nordiskâs end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.
GSK Plc., will pay Chinaâs privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.